May 18, 2026 07:01AM
May 18, 2026 07:00AM
May 13, 2026 07:00AM
May 13, 2026 07:00AM
Apr 30, 2026 08:31AM
Apr 30, 2026 08:31AM
Mar 26, 2026 09:28AM Can-Fite BioPharma reports net loss widens to $9.83 million in 2025
Mar 26, 2026 09:27AM
Mar 17, 2026 07:47AM
Mar 17, 2026 07:47AM
Mar 4, 2026 10:26AM
Mar 4, 2026 10:25AM
Mar 4, 2026 07:02AM
Dec 23, 2025 04:47PM Can-Fite announces 1-for-3,000 reverse stock split effective January 2026
Dec 23, 2025 04:46PM
Dec 16, 2025 09:19AM
Dec 16, 2025 09:19AM
Nov 26, 2025 07:01AM
Nov 26, 2025 07:00AM
Jul 30, 2025 07:04AM
Jul 30, 2025 07:04AM Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Jul 28, 2025 12:24PM
Jul 28, 2025 12:24PM
Apr 14, 2025 02:29PM
Apr 14, 2025 02:28PM
Apr 14, 2025 08:01AM
Apr 14, 2025 08:00AM
Mar 24, 2025 09:00AM Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Feb 18, 2025 07:00AM
Feb 10, 2025 07:10AM
Feb 5, 2025 07:00AM
Jan 27, 2025 07:00AM
Nov 12, 2024 07:51AM
Nov 4, 2024 07:12AM
Nov 4, 2024 07:08AM Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Oct 18, 2024 09:11AM
Oct 18, 2024 09:06AM
Oct 7, 2024 07:00AM
Sep 16, 2024 07:00AM
Aug 29, 2024 08:17AM
Aug 29, 2024 08:15AM
Jul 17, 2024 07:00AM Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
Jun 28, 2024 07:00AM
Jun 28, 2024 07:00AM
Jun 24, 2024 07:00AM
Jun 24, 2024 07:00AM
Jun 10, 2024 07:00AM
Jun 5, 2024 07:03AM
Jun 5, 2024 07:00AM Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
May 29, 2024 07:00AM

323,002 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All